The company’s lead drug candidate, GO-203-2c is currently being studied in a Phase I trial which aims to determine the safety and tolerability, and potential anti-tumor activity of the drug.
Genus Oncology president and CEO Stephen Thompson said based on their results of treating pancreatic cancer in preclinical models, they believe MUC1 targeting technologies have the potential to significantly impact the treatment and outcomes of this difficult to treat disease.